Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy

Miller, R F; Allen, Edward D.; Copas, Andrew; Singer, Mervyn; Edwards, Simon

doi:10.1136/thx.2005.055905

Cited by 100 publications

(99 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of HAART in this study was found to be an independent predictor of decreased mortality after adjusting for other factors (eg, mechanical ventilation, pneumothorax, delay in initiation of antipneumocystis treatment) that previously have been shown to influence survival [17]. In contradiction to the above study, Miller et al [18] demonstrated an improved survival in patients admitted to the ICU with PCP independent of HAART therapy. Authors attribute this finding to improved ICU management and the adoption of the low tidal volume strategy in patients with PCP and respiratory failure requiring mechanical ventilation [18].…”

Section: Pneumocystis Pneumoniamentioning

confidence: 57%

Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: An update

Lazarous

O’Donnell

2007

Curr Infect Dis Rep

View full text Add to dashboard Cite

The highly active antiretroviral therapy (HAART) era began in 1996 when the combination of multiple antiretroviral agents was found to improve outcomes in HIV-infected patients. HAART has made a tremendous impact on the progression of HIV and on the morbidity and mortality associated with its opportunistic infections. HIV-positive patients who respond to HAART have a decreased incidence of opportunistic infections. Studies have documented close to a 50% decline in the incidence of pneumocystis pneumonia and bacterial pneumonia with the use of antiretroviral therapy. Primary and secondary prophylaxis for pneumocystis pneumonia can be discontinued in patients who show a sustained response to antiretroviral therapy. Unique to the HAART era, immune reconstitution syndrome is characterized by a paradoxical deterioration of a preexisting infection that is temporally related to the recovery of the immune system. Recently, more and more patients are being admitted for non-AIDS related illnesses in the HAART era.

show abstract

Section: Pneumocystis Pneumoniamentioning

confidence: 57%

Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: An update

Lazarous

O’Donnell

2007

Curr Infect Dis Rep

View full text Add to dashboard Cite

show abstract

“…However, specific HIV characteristics (CD4 cell count, plasma HIV-RNA load, HIV-related diagnosis, or antiretroviral therapy) have not been clearly identified as predictors of ICU mortality [4,15,37,38,[49][50][51][52][54][55][56][57][58][59], although some reports have associated CD4…”

Section: Discussionmentioning

confidence: 99%

Mortality of patients infected with HIV in the intensive care unit (2005-2010): significant role of chronic hepatitis C and severe sepsis

Medrano¹,

Álvaro-Meca²,

Boyer³

et al. 2014

Critical Care

View full text Add to dashboard Cite

“…Mortality in critically ill PCP patients remains high, with recent estimates of 29 to 62% for PCP patients admitted to intensive care (48,65,152,221,250). Factors associated with increased mortality risk in critically ill patients with PCP include higher age, lower serum albumin, need for mechanical ventilation, development of a pneumothorax, greater alveolar-arterial oxygen gradient, and lower hemoglobin (2,79,92,150,208,221,250,313). Some studies have reported that a lower CD4 ϩ cell count is associated with a greater mortality, but not all cohorts have replicated this result (79,92,150,250).…”

Section: Recent Epidemiology Of Pcp In Hiv-infected Patientsmentioning

confidence: 99%

Colonization by Pneumocystis jirovecii and Its Role in Disease

2012

View full text Add to dashboard Cite

SUMMARY Although the incidence of Pneumocystis pneumonia (PCP) has decreased since the introduction of combination antiretroviral therapy, it remains an important cause of disease in both HIV-infected and non-HIV-infected immunosuppressed populations. The epidemiology of PCP has shifted over the course of the HIV epidemic both from changes in HIV and PCP treatment and prevention and from changes in critical care medicine. Although less common in non-HIV-infected immunosuppressed patients, PCP is now more frequently seen due to the increasing numbers of organ transplants and development of novel immunotherapies. New diagnostic and treatment modalities are under investigation. The immune response is critical in preventing this disease but also results in lung damage, and future work may offer potential areas for vaccine development or immunomodulatory therapy. Colonization with Pneumocystis is an area of increasing clinical and research interest and may be important in development of lung diseases such as chronic obstructive pulmonary disease. In this review, we discuss current clinical and research topics in the study of Pneumocystis and highlight areas for future research.

show abstract

Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy

Cited by 100 publications

References 49 publications

Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: An update

Pulmonary infections in the HIV-infected patient in the era of highly active antiretroviral therapy: An update

Mortality of patients infected with HIV in the intensive care unit (2005-2010): significant role of chronic hepatitis C and severe sepsis

Colonization by Pneumocystis jirovecii and Its Role in Disease

Contact Info

Product

Resources

About